Charlottte (Talk | contribs) |
Charlottte (Talk | contribs) |
||
Line 497: | Line 497: | ||
<div class="click" id="btm1"> | <div class="click" id="btm1"> | ||
<img src="https://static.igem.org/mediawiki/parts/f/f6/Wiki_C.png" class="locat"> | <img src="https://static.igem.org/mediawiki/parts/f/f6/Wiki_C.png" class="locat"> | ||
− | <a href=" | + | <a href="https://2016.igem.org/Team:SCUT-China_B/Overview"><br/>Overview</a> |
</div> | </div> | ||
<div class="click" id="btm2"> | <div class="click" id="btm2"> | ||
<img src="https://static.igem.org/mediawiki/parts/f/f6/Wiki_C.png" class="locat"> | <img src="https://static.igem.org/mediawiki/parts/f/f6/Wiki_C.png" class="locat"> | ||
− | <a href=" | + | <a href="https://2016.igem.org/Team:SCUT-China_B/Propoptosis">Apoptosis Induction</a> |
</div> | </div> | ||
<div class="click" id="btm3"> | <div class="click" id="btm3"> | ||
<img src="https://static.igem.org/mediawiki/parts/f/f6/Wiki_C.png" class="locat"> | <img src="https://static.igem.org/mediawiki/parts/f/f6/Wiki_C.png" class="locat"> | ||
− | <a href=" | + | <a href="https://2016.igem.org/Team:SCUT-China_B/Protumor">Tumor specific promoter</a> |
</div> | </div> | ||
</div> | </div> |
Revision as of 18:11, 28 November 2016
Non-small cell lung cancer (NSCLC)
While Lung cancer is a common kind of cancer, non-small cell lung cancer belongs to lung cancer and takes the percentage of 80%-85% .Unlike most lung cancer , non-small cell cancer usually appears to occur in people who do not smoke.
According to the WHO Health statistics [1], the death rate of lung cancer is on the top among cancers. In particular, it is the leading cause of cancer death among males in both developed and undeveloped countries.
![](https://static.igem.org/mediawiki/parts/a/aa/Wiki_project_1.jpg)
Figure 1. Death rate among cancers around the world, according to WHO Health statistics.
Therapy for NSCLC
![](https://static.igem.org/mediawiki/parts/7/77/Wiki_project_2.png)
Figure 2. According to Nccn clinical practice guidelines in oncology, non-small cell cancer. Current therapy for NSCLC[2], mainly consists of traditional therapy, small-molecule targeted drugs and cancer immunotherapy.